Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 25;17(7):e0270591.
doi: 10.1371/journal.pone.0270591. eCollection 2022.

Molecular characterization of gastric adenocarcinoma diagnosed in patients previously treated for Hodgkin lymphoma or testicular cancer

Affiliations

Molecular characterization of gastric adenocarcinoma diagnosed in patients previously treated for Hodgkin lymphoma or testicular cancer

Lisanne S Rigter et al. PLoS One. .

Abstract

Introduction: The risk of developing gastric cancer is increased in patients treated with radiotherapy for Hodgkin lymphoma (HL) or testicular cancer (TC). This study aims to assess if gastric adenocarcinoma after treatment for HL/TC (t-GC) is molecularly different from gastric adenocarcinoma in the general population.

Methods: Patients were diagnosed with t-GC ≥5 years after treatment for HL/TC. Four molecular subtypes were identified using immunohistochemical and molecular analyses: Epstein-Barr virus (EBV), mismatch repair (MMR) deficiency or microsatellite instability (MSI), aberrant p53 staining as surrogate for chromosomal instability (sCIN), and a surrogate for genomic stability (sGS) without these aberrations. Results were compared with gastric cancer in the general population (p-GC) described in literature.

Results: Molecular subtyping of 90 t-GCs resulted in 3% EBV, 8% MSI, 36% sCIN and 53% sGS. 3/6 of MSI t-GCs had MLH1 promoter methylation and 2/6 were explained by double somatic mutations in MMR genes. T-GCs were more frequently sGS than p-GCs (53% vs. 38%, p = 0.04). T-GC was more frequently sGS in HL/TC patients diagnosed before 1990, than after 1990 (63% vs. 38%, p = 0.03). T-GCs located in the antrum, an area that receives high irradiation doses, were more frequently sGS (61% vs. 28% in p-GCs, p = 0.02).

Conclusion: Our results demonstrate that t-GCs are more frequently of the sGS subtype than p-GCs. An association of t-GC of the sGS subtype with prior anticancer treatment is suggested by the high frequency in HL/TC patients who were treated before 1990, a time period in which HL/TC treatments were more extensive.

PubMed Disclaimer

Conflict of interest statement

The authors have declared no conflict of interest.

Figures

Fig 1
Fig 1. Distribution of molecular subtypes and Lauren classification across locations of gastric cancer after treatment for Hodgkin lymphoma or testicular cancer.
Abbreviations: GEJ, gastroesophageal junction; EBV, Epstein-Barr virus; MSI, microsatellite instability; CIN, chromosomal instability; GS, genomic stability.
Fig 2
Fig 2. Molecular subtype distribution of gastric cancer after treatment for Hodgkin lymphoma or testicular cancer and gastric cancer in the general population.
A: overall comparison of molecular subgroup distributions between t-GC and p-GC. B: molecular subgroup comparison between t-GC and p-GC after selection of Lauren classification. C: molecular subgroup comparison between t-GC and p-GC after selection of gastric cancer location. Abbreviations: EBV, Epstein-Barr virus; MSI, microsatellite instability; sCIN, surrogate chromosomal instability; sGS, surrogate genomic stability; t-GC, gastric cancer after treatment for Hodgkin lymphoma or testicular cancer; p-GC, gastric cancer in the general population; GEJ, gastroesophageal junction. * p<0.05, statistically significant difference between t-GC and p-GC groups.

Similar articles

Cited by

References

    1. Gilbert ES, Curtis RE, Hauptmann M, et al.. Stomach Cancer Following Hodgkin Lymphoma, Testicular Cancer and Cervical Cancer: A Pooled Analysis of Three International Studies with a Focus on Radiation Effects. Radiat Res 2017;187:186–195. doi: 10.1667/RR14453.1 - DOI - PMC - PubMed
    1. Morton LM, Dores GM, Curtis RE, et al. Stomach cancer risk after treatment for hodgkin lymphoma. J Clin Oncol 2013;31:3369–77. doi: 10.1200/JCO.2013.50.6832 - DOI - PMC - PubMed
    1. Birdwell SH, Hancock SL, Varghese A, et al. Gastrointestinal cancer after treatment of Hodgkin’s disease. Int J Radiat Oncol Biol Phys 1997;37:67–73. doi: 10.1016/s0360-3016(96)00489-0 - DOI - PubMed
    1. Hodgson DC, Gilbert ES, Dores GM, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin’s lymphoma. J Clin Oncol 2007;25:1489–97. doi: 10.1200/JCO.2006.09.0936 - DOI - PubMed
    1. Schaapveld M, Aleman BM, van Eggermond AM, et al. Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma. N Engl J Med 2015;373:2499–511. doi: 10.1056/NEJMoa1505949 - DOI - PubMed

Publication types

Supplementary concepts